Neisseria meningitidis group C capsular polysaccharide-tetanus toxoid conjugate (MenC-TT)

The Neisseria meningitidis group C capsular polysaccharide-tetanus toxoid conjugate (MenC-TT) is a specific vaccine formulation designed to overcome the limitations of pure polysaccharide antigens. While serogroup C polysaccharides are naturally T-cell independent, their conjugation to a tetanus toxoid carrier protein allows for recognition by the human adaptive immune system through a T-cell dependent pathway (Pollard et al., 2009, Nature Reviews Immunology). This interaction involves the uptake of the conjugate by antigen-specific B cells, followed by the presentation of carrier-derived peptides to CD4+ T cells. This process is essential for inducing high-affinity IgG antibodies and establishing long-term immunological memory, which is not possible with polysaccharide-only vaccines (Pace et al., 2009, Vaccine). MenC-TT is a key component in vaccines such as NeisVac-C and Nimenrix, which are used to prevent life-threatening invasive meningococcal diseases like meningitis and septicemia (Snape & Pollard, 2005, Lancet Infectious Diseases). The efficacy of drugs targeting this system is typically monitored through serum bactericidal antibody (SBA) assays, which measure the functional ability of induced antibodies to kill Neisseria meningitidis.

Other names

Meningococcal group C conjugate vaccineMenC-TNeisseria meningitidis serogroup C conjugateMenC-tetanus toxoid

The polysaccharide antigen is covalently linked to a tetanus toxoid carrier protein to convert a T-cell independent response into a T-cell dependent response, enabling B-cell memory and high-affinity antibody production.